Myatorlip (Atorvastatin, Ezetimibe)

Atorvastatin and ezetimibe, the active ingredients in Myatorlip, are a statin and a cholesterol absorption inhibitor presented as an oral tablet for oral use. They are prescribed to lower elevated blood lipids in adults with primary hypercholesterolemia, mixed dyslipidemia, or those needing cardiovascular risk reduction.

GNH USA supplies Myatorlip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Myatorlip is used to manage lipid disorders and reduce cardiovascular risk. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: improves the balance of LDL, HDL and triglycerides. - Primary prevention of cardiovascular disease: reduces the likelihood of heart attack and stroke in at‑risk patients.

Myatorlip may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Gastrointestinal discomfort (e.g., nausea, abdominal pain) - Muscle pain or weakness - Elevated liver enzymes - Fatigue - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis - Severe liver injury (hepatitis) - Allergic reactions such as rash or angioedema - Myopathy - Acute pancreatitis - Hepatic failure

When prescribing Myatorlip, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess hepatic enzymes before initiation and periodically during therapy. - Muscle toxicity vigilance: advise patients to report unexplained muscle pain, weakness or dark urine. - Drug interactions: review concomitant medications that may increase statin exposure. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk. - Renal impairment: adjust therapy in patients with severe renal dysfunction. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Myatorlip can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) - Gemfibrozil - Cyclosporine - High‑dose niacin - Warfarin (may increase INR)

Moderate Interactions (Monitor Closely): - Other statins or fibrates - Digoxin - Antacids (may reduce ezetimibe absorption) - Grapefruit juice - Amiodarone